Magic Mushroom Compound May Stop Chemo Nerve Damage

Chemotherapy saves lives, but it often leaves cancer patients with burning, tingling nerves that sometimes never heal. Now scientists have found an unexpected ally in the fight against this painful side effect: the psychedelic compound in magic mushrooms.

Researchers at MD Anderson Cancer Center discovered that psilocybin completely prevented nerve damage in mice receiving chemotherapy. Just two doses given before treatment protected the animals through six full rounds of cancer drugs, according to a study published in the journal Science.

The finding matters because nerve damage affects up to half of all patients receiving certain chemotherapies. Some cases become so severe that doctors must reduce or stop cancer treatment entirely, leaving patients caught between fighting their disease and living with excruciating pain.

The team wasn't even looking for a neuropathy treatment when they made the discovery. They were testing compounds that help the nervous system adapt and change, hoping to improve existing cancer treatments. Psilocybin emerged as the clear winner among several psychedelic compounds tested.

The secret lies in how nerve cells get their fuel. Neurons stretch enormous distances through the body, and their power plants called mitochondria must travel along internal tracks to reach nerve endings. Chemotherapy damages both the mitochondria and the tracks they travel on, leaving nerve endings starving for energy.

Psilocybin doesn't boost the mitochondria's overall power output. Instead, it keeps them moving and maintains energy production right where nerves need it most. The drug appears to protect the cellular railroad system that keeps distant nerve endings alive and functioning.

Why This Inspires

Cancer treatment has always involved difficult tradeoffs between fighting disease and enduring brutal side effects. This research opens a door to something different: protecting healthy tissue while still destroying cancer cells.

The discovery becomes even more exciting because researchers created a non-psychedelic version that also worked in mice. That means patients might gain the protective benefits without experiencing hallucinations, though scientists caution the psychedelic effects themselves might play a helpful role we don't yet understand.

Dr. Thomas Strouse, a UCLA neuropathy researcher not involved in the study, called nerve damage prevention "a big deal, big problem" that scientists have searched to solve for decades. The missing piece may have been hiding in an unexpected place all along.

The team is now preparing human trials at MD Anderson to test whether psilocybin can protect cancer patients the same way it protected mice. Different chemotherapy drugs may damage nerves through different mechanisms, so researchers need to verify the approach works broadly before patients can benefit.

For the millions facing chemotherapy each year, this research offers genuine hope that debilitating nerve damage might become preventable rather than inevitable.